A the recent CRGC/FDA meeting, Dr. Diaa Shakleya presented a study on the screening and effectiveness of potential scavengers to prevent Nitroso-API formation.
This week a team from FDA published “Bumetanide as a Model NDSRI Substrate: N-nitrosobumetanide impurity formation and its inhibition in bumetanide tablets”